Potential Value of Expression of Receptor Accessory Protein 4 for Evaluating the Prognosis of Lower-grade Glioma Patients

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Mar 29

PMID 38552216

Authors

Shuping Luo

Zhendong Liu

Haigang Chang

Xingbo Cheng

Rongjun Qian

Yanzheng Gao

Chaofeng Hou

Affiliations

Soon will be listed here.

Abstract

Background: REEP4 is involved in the regulation of the biological process of mitosis. Lower grade glioma (LGG), as a malignant tumor, is accompanied by abnormalities in mitosis, but there have been no reports of REEP4 so far.

Methods: We collected transcriptome data, DNA methylation data and the clinical characteristics of thousands of patients with LGG. Various big data analysis methods and molecular biology experiments were employed to reveal the impact of REEP4 on the pathological process of LGG.

Results: It was found that the expression of REEP4 was significantly elevated and negatively regulated by its methylation site. Therefore, both the high expression of REEP4 and low methylation state of cg16311504 showed that the patients are correlated with lower patient survival rate. In addition, high REEP4 expression participates in the regulation of various cancer-related cellular signaling pathways, such as the cell cycle, MAPK signaling pathway, NOD-like receptor signaling pathway, etc. More importantly, the level of immune cell infiltration significantly increased in the high expression group of REEP4 in the LGG tumor microenvironment and REEP4 has a high positive correlation with PD-L1 and other immune checkpoints.

Conclusions: In brief, this study is the first to introduce REEP4 in malignant tumors, which can be used as an independent risk factor that participates in the malignant process of LGG. More importantly, REEP4 has the potential to become a new star in the field of anti-tumor treatment.

References

Yu Y, Li Y, Zhou L, Yang G, Wang M, Hong Y . Cryptochrome 2 (CRY2) Suppresses Proliferation and Migration and Regulates Clock Gene Network in Osteosarcoma Cells. Med Sci Monit. 2018; 24:3856-3862. PMC: 6020744. DOI: 10.12659/MSM.908596. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Liu X, Chen Y, Li Y, Petersen R, Huang K . Targeting mitosis exit: A brake for cancer cell proliferation. Biochim Biophys Acta Rev Cancer. 2019; 1871(1):179-191. DOI: 10.1016/j.bbcan.2018.12.007. View

Liu Z, Wang X, Yang G, Zhong C, Zhang R, Ye J . Construction of lncRNA-associated ceRNA networks to identify prognostic lncRNA biomarkers for glioblastoma. J Cell Biochem. 2020; 121(7):3502-3515. DOI: 10.1002/jcb.29625. View

Zhao Z, Zhang K, Wang Q, Li G, Zeng F, Zhang Y . Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics Proteomics Bioinformatics. 2021; 19(1):1-12. PMC: 8498921. DOI: 10.1016/j.gpb.2020.10.005. View

Lv S, Li Y, Ning H, Zhang M, Jia Q, Wang X . CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis. Sci Rep. 2021; 11(1):386. PMC: 7801409. DOI: 10.1038/s41598-020-79321-y. View

Yuen V, Chak-Lui Wong C . Hypoxia-inducible factors and innate immunity in liver cancer. J Clin Invest. 2020; 130(10):5052-5062. PMC: 7524494. DOI: 10.1172/JCI137553. View

Lin W, Ou G, Zhao W . Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. J Cell Mol Med. 2021; 25(21):10111-10125. PMC: 8572778. DOI: 10.1111/jcmm.16947. View

Zhan Sheng Z . Anticancer effects of catechin flavonoid in human glioma cells are mediated via autophagy induction, cell cycle arrest, inhibition of cell migration and invasion and targeting MAPK/ERK signalling pathway. J BUON. 2020; 25(2):1084-1090. View

10.

Mehta A, Gracias D, Croft M . TNF activity and T cells. Cytokine. 2016; 101:14-18. PMC: 5305780. DOI: 10.1016/j.cyto.2016.08.003. View

11.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

12.

Golchoubian B, Brunner A, Bragulat-Teixidor H, Neuner A, Akarlar B, Ozlu N . Reticulon-like REEP4 at the inner nuclear membrane promotes nuclear pore complex formation. J Cell Biol. 2021; 221(2). PMC: 8656412. DOI: 10.1083/jcb.202101049. View

13.

Yu H, Zhang D, Lian M . Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neurosci Ther. 2021; 27(4):470-483. PMC: 7941239. DOI: 10.1111/cns.13587. View

14.

Xu H, Zhang A, Han X, Li Y, Zhang Z, Song L . ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunol Immunother. 2021; 71(3):645-660. PMC: 10992927. DOI: 10.1007/s00262-021-03022-2. View

15.

Qi C, Lei L, Hu J, Wang G, Liu J, Ou S . Identification of a five-gene signature deriving from the vacuolar ATPase (V-ATPase) sub-classifies gliomas and decides prognoses and immune microenvironment alterations. Cell Cycle. 2022; 21(12):1294-1315. PMC: 9132400. DOI: 10.1080/15384101.2022.2049157. View

16.

Shi F, He Y, Li J, Tang M, Li Y, Xie L . Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. Mol Metab. 2020; 36:100966. PMC: 7109632. DOI: 10.1016/j.molmet.2020.02.009. View

17.

Liu Z, Cheng X, Pang B, Wang S, Liu B, Cao C . Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma. Int Immunopharmacol. 2022; 104:108399. DOI: 10.1016/j.intimp.2021.108399. View

18.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

19.

Karin N . Chemokines and cancer: new immune checkpoints for cancer therapy. Curr Opin Immunol. 2018; 51:140-145. DOI: 10.1016/j.coi.2018.03.004. View

20.

Ouyang Y, Wu Q, Li J, Sun S, Sun S . S-adenosylmethionine: A metabolite critical to the regulation of autophagy. Cell Prolif. 2020; 53(11):e12891. PMC: 7653241. DOI: 10.1111/cpr.12891. View